Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
基本信息
- 批准号:9887570
- 负责人:
- 金额:$ 62.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-03 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AgglutininsAntibodiesAvian Influenza A VirusAvidityBindingBiological AssayBiologyBirdsCellsChickensDropsEndothelial CellsEnzyme-Linked Immunosorbent AssayEpithelial CellsEpithelial Receptor CellEquilibriumErythrocytesEvolutionExhibitsGalanthusGleanGoalsGrowthHemagglutininHorseradish PeroxidaseHumanHuman ActivitiesImmuneImmunodominant EpitopesInfectionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza HemagglutininKineticsKnowledgeLaboratoriesLibrariesLightLinkMDCK cellMeleagris gallopavoMethodsModelingMutationNasal EpitheliumNeuraminidaseNosePolysaccharidesPopulationProductionPropertyProteinsRecombinantsRecoveryRiskRoleST14 geneSialic AcidsSoft PalateSpecificitySpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStructureSurface AntigensSurveysTimeTracheal EpitheliumVaccine ProductionVaccinesVariantVirusVirus ReceptorsVirus Sheddingairway epitheliumbasechorioallantoic membraneeggfitnessflu activityimprovedinfluenzaviruslactosaminemortalitynovelpandemic diseasepreferencepressurereceptorreceptor bindingtooltransmission processvaccine efficacy
项目摘要
Influenza virus causes worldwide seasonal infections and occasional pandemics with high mortality rate.
Human viruses are known to have a preference for α2-6 linked sialic acids (NeuAcα2-6Gal), while avian
viruses exhibit a preference for α2-3 linked sialic acids (NeuAcα2-3Gal). This difference in receptor specificity
is widely considered a major species barrier for transmission of avian viruses in the human population.
Although this binary model of receptor specificity has been useful, it belies the true complexity of sialic acid
containing glycans on host cells and has becoming increasingly limiting since the receptor binding properties
of influenza viruses continue to evolve. The use of glycan microarrays with dozens of α2-3 and α2-6 linked
glycans has shown that influenza viruses evolve by restricting their specificity to specific glycans within those
broad groups. However, interpretation of these findings for their relevance to influenza biology is uncertain
since there is little information about the types of glycans that are actually present on human airway
epithelium, and whether relevant airway epithelium glycans are represented on glycan microarrays. This
project aims to identify the glycan structures on human airway epithelial cells that bind human influenza virus
and expand glycan array libraries to include them, 2) to determine how the specificity and activity of human
influenza virus hemagglutinins (HAs) and neuraminidases (NAs) evolve under immune selective pressure to
retain their ability to interact with human airway receptors and 3) to use the information gleaned about
receptor specificity to develop reliable methods for analysis and propagation of influenza in the laboratory.
This information will identify receptor determinants on the human airway that are shared by human influenza
viruses, and shed light on properties of the HA and NA that contribute to pandemic risk of influenza viruses
from avian viruses that occasionally infect humans.
流感病毒引起世界范围内的季节性感染和偶尔的大流行,死亡率很高。
已知人类病毒偏爱α2-6连接唾液酸(NeuAcα2-6Gal),而禽类病毒
病毒表现出对α2-3连接唾液酸(NeuAcα2-3Gal)的偏好。这种受体特异性的差异
被广泛认为是禽流感病毒在人类种群中传播的主要物种障碍。
尽管这种受体专一性的二元模型很有用,但它掩盖了唾液酸的真正复杂性。
在宿主细胞上含有多糖,并且由于受体结合特性而变得越来越有限
流感病毒的数量仍在继续进化。使用与数十个α2-3和α2-6相连的葡聚糖微阵列
多糖已经表明,流感病毒的进化是通过将其特异性限制在那些
广泛的群体。然而,对这些发现与流感生物学的相关性的解释尚不确定。
因为关于人体呼吸道中实际存在的多糖类型的信息很少
上皮细胞,以及相关的呼吸道上皮多糖是否存在于多聚糖微阵列上。这
该项目旨在鉴定与人类流感病毒结合的人呼吸道上皮细胞上的糖链结构
并扩展糖链阵列文库以包括它们,2)确定人的特异性和活性
流感病毒血凝素(Has)和神经氨酸酶(Nas)在免疫选择性压力下进化
保留它们与人类呼吸道受体相互作用的能力,以及3)使用收集到的信息
受体特异性,以开发可靠的方法,在实验室分析和繁殖流感。
这一信息将确定人类呼吸道上与人类流感共享的受体决定因素
并阐明了导致流感病毒大流行风险的HA和NA的特性
来自偶尔感染人类的禽类病毒。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES C PAULSON其他文献
JAMES C PAULSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES C PAULSON', 18)}}的其他基金
Removing sialic acid ligands of CD28 to enhance T cell cancer immunotherapy
去除CD28的唾液酸配体以增强T细胞癌症免疫治疗
- 批准号:
10668007 - 财政年份:2023
- 资助金额:
$ 62.41万 - 项目类别:
Exploiting inhibitory Siglecs for desensitizing mast cells
利用抑制性 Siglecs 使肥大细胞脱敏
- 批准号:
10219077 - 财政年份:2018
- 资助金额:
$ 62.41万 - 项目类别:
Siglec-targeted nanoparticles for treating mast cell mediated allergic disease
Siglec 靶向纳米颗粒用于治疗肥大细胞介导的过敏性疾病
- 批准号:
10331726 - 财政年份:2018
- 资助金额:
$ 62.41万 - 项目类别:
Exploiting inhibitory Siglecs for desensitizing mast cells
利用抑制性 Siglecs 使肥大细胞脱敏
- 批准号:
9789823 - 财政年份:2018
- 资助金额:
$ 62.41万 - 项目类别:
Exploiting inhibitory Siglecs for desensitizing mast cells
利用抑制性 Siglecs 使肥大细胞脱敏
- 批准号:
10468007 - 财政年份:2018
- 资助金额:
$ 62.41万 - 项目类别:
Siglec-targeted nanoparticles for treating mast cell mediated allergic disease
Siglec 靶向纳米颗粒用于治疗肥大细胞介导的过敏性疾病
- 批准号:
10097996 - 财政年份:2018
- 资助金额:
$ 62.41万 - 项目类别:
Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
- 批准号:
10226011 - 财政年份:2015
- 资助金额:
$ 62.41万 - 项目类别:
Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
- 批准号:
8963149 - 财政年份:2015
- 资助金额:
$ 62.41万 - 项目类别:
Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
- 批准号:
9233896 - 财政年份:2015
- 资助金额:
$ 62.41万 - 项目类别:
Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
- 批准号:
10676798 - 财政年份:2015
- 资助金额:
$ 62.41万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 62.41万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 62.41万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 62.41万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 62.41万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 62.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 62.41万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 62.41万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 62.41万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 62.41万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 62.41万 - 项目类别:














{{item.name}}会员




